Abstract
Abstract We are presently at a crossroads in clinical practice as new public health models for cervical cancer prevention and detection are being developed and tested. In the US, we are in the midst of redefining government policy and medical decision-making based on human papillomavirus (HPV) natural history studies, randomized trials, and prophylactic vaccine uptake. Novel diagnostic, progression and treatment approaches are emerging that are based on a paradigm that recognizes the central role of HPV persistence in anogenital cancer development. Gaps in epidemiological and clinical research will be examined including the role of immune markers in viral clearance, the transmission dynamics of anogenital HPV infection, novel screening modalities in high risk populations, and the implementation of population-based surveillance activities to determine the public health benefit and cost-effectiveness of the prophylactic HPV vaccine. Citation Information: Cancer Prev Res 2011;4(10 Suppl):CN02-03.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
